LLY

751.96

-3.18%↓

JNJ

155.56

-1.06%↓

UNH

385.73

-1.37%↓

ABBV

185.44

-1.29%↓

ABT

133.82

-0.01%↓

LLY

751.96

-3.18%↓

JNJ

155.56

-1.06%↓

UNH

385.73

-1.37%↓

ABBV

185.44

-1.29%↓

ABT

133.82

-0.01%↓

LLY

751.96

-3.18%↓

JNJ

155.56

-1.06%↓

UNH

385.73

-1.37%↓

ABBV

185.44

-1.29%↓

ABT

133.82

-0.01%↓

LLY

751.96

-3.18%↓

JNJ

155.56

-1.06%↓

UNH

385.73

-1.37%↓

ABBV

185.44

-1.29%↓

ABT

133.82

-0.01%↓

LLY

751.96

-3.18%↓

JNJ

155.56

-1.06%↓

UNH

385.73

-1.37%↓

ABBV

185.44

-1.29%↓

ABT

133.82

-0.01%↓

Search

Durect Corp

Fermé

0.63 10.53

Résumé

Variation du prix de l'action

24h

Actuel

Min

0.55

Max

0.65

Chiffres clés

By Trading Economics

Employés

21

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+1063.79% upside

Dividendes

By Dow Jones

Prochains Résultats

12 mai 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-6.8M

17M

Ouverture précédente

-9.9

Clôture précédente

0.63

Durect Corp Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

8 mai 2025, 23:59 UTC

Actualités
Résultats

Naver 1Q Net Slumps on Higher Costs

8 mai 2025, 23:39 UTC

Résultats

OCBC 1Q Net Down on Lower Interest Income

8 mai 2025, 23:01 UTC

Résultats

Macquarie Raises Dividend After 5.5% Rise in Annual Profit -- Update

8 mai 2025, 22:52 UTC

Résultats

REA Expects Annual Listings Growth Despite April Decline

8 mai 2025, 22:46 UTC

Résultats

Macquarie Raises Dividend After 5.5% Rise in Annual Profit

8 mai 2025, 23:45 UTC

Market Talk

Global Equities Roundup: Market Talk

8 mai 2025, 23:45 UTC

Market Talk

Nikkei May Rise as Tariffs Fears Ease -- Market Talk

8 mai 2025, 23:41 UTC

Market Talk

Gold Rises on Possible Technical Recovery; Gains May be Capped by Risk-on Mood -- Market Talk

8 mai 2025, 23:30 UTC

Résultats

Itau Unibanco 1Q Rev BRL45.02B >ITUB

8 mai 2025, 23:29 UTC

Résultats

Itau Unibanco 1Q EPS BRL1.03 >ITUB

8 mai 2025, 23:22 UTC

Résultats

Naver 1Q Net Profit Largely Met FactSet-Compiled Consensus

8 mai 2025, 23:22 UTC

Résultats

Naver 1Q Net KRW423.70B Vs. Net KRW555.80B >035420.SE

8 mai 2025, 23:21 UTC

Résultats

Naver 1Q Oper Pft KRW505.30B Vs. Pft KRW439.30B >035420.SE

8 mai 2025, 23:21 UTC

Résultats

Naver 1Q Rev KRW2.787T Vs. KRW2.526T >035420.SE

8 mai 2025, 23:17 UTC

Résultats

Oversea-Chinese Banking Corp. 1Q Net Interest Income S$2.35B Vs. S$2.44B >O39.SG

8 mai 2025, 23:17 UTC

Résultats

Oversea-Chinese Banking Corp. 1Q Total Income S$3.66B Vs. S$3.63B >O39.SG

8 mai 2025, 23:17 UTC

Résultats

Oversea-Chinese Banking Corp. 1Q Net S$1.88B Vs. Net S$1.98B >O39.SG

8 mai 2025, 23:05 UTC

Market Talk

ANZ Could Cut Dividend by 10% From 2H -- Market Talk

8 mai 2025, 23:05 UTC

Market Talk

Global Equities Roundup: Market Talk

8 mai 2025, 22:28 UTC

Résultats

REA Expects FY 2025 Listings Growth of 1-2%

8 mai 2025, 22:28 UTC

Résultats

REA Says April Listings Decline Reflects Year Ago Strength, Timing of Easter and Election

8 mai 2025, 22:27 UTC

Résultats

REA Says April Sydney, Melbourne Listings Both Down 16% on Year

8 mai 2025, 22:27 UTC

Résultats

REA Says April Residential Listings Fell by 11% on Year

8 mai 2025, 22:26 UTC

Résultats

REA 3Q Operating Expenses A$176 Million, Up 12% on Year

8 mai 2025, 22:26 UTC

Résultats

REA 3Q Free Cash Flow A$132 Million, Up 19% on Year

8 mai 2025, 22:26 UTC

Résultats

REA 3Q Operating Ebitda A$199 Million, Up 12% on Year

8 mai 2025, 22:26 UTC

Résultats

REA Nine-Months Free Cash Flow A$389 Million, Up 21% on Year

8 mai 2025, 22:25 UTC

Résultats

REA Nine-Months Operating Expenses A$513 Million, Up 15% on Year

8 mai 2025, 22:25 UTC

Résultats

REA Nine-Months Operating Ebitda A$734 Million, Up 19% on Year

8 mai 2025, 22:25 UTC

Résultats

REA 3Q Revenue A$374 Million, Up 12% on Year

Comparaison

Variation de prix

Durect Corp prévision

Objectif de Prix

By TipRanks

1063.79% hausse

Prévisions sur 12 Mois

Moyen 6.75 USD  1063.79%

Haut 8.5 USD

Bas 5 USD

Basé sur 3 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

3 ratings

2

Achat

1

Maintien

0

Vente

Éléments financiers

$

À Propos Durect Corp

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. It also offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in other countries. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.